LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
LABCORP HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$318.83+0.88 (+0.28%)
Close on Oct 19, 2026
- Market cap
- $26.14B
- P/E (TTM)
- 26.4
- Dividend yield
- 0.90%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
98.0%
79M of 81M shares
Institutional holders
1,043
107 new, 72 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 21 sales
Net sold $13.70M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 6,331,017 | 7.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 6,201,512 | 7.52% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,574,261 | 8.11% | $1.84B | +129,405 | 0.03% |
| Vanguard Capital Management LLC | 5,362,254 | 6.61% | $1.50B | −13,866 | 0.03% |
| Victory Capital Management Inc | 4,837,573 | 5.96% | $1.35B | +210,447 | 0.76% |
| State Street Corp | 3,907,656 | 4.82% | $1.09B | +44,485 | 0.03% |
| Vanguard Portfolio Management LLC | 3,678,798 | 4.54% | $1.03B | −1,863 | 0.05% |
| Boston Partners | 3,051,690 | 3.76% | $854.20M | +682,894 | 0.76% |
| Allspring Global Investments Holdings, LLC | 2,236,957 | 2.76% | $635.03M | +10,511 | 0.97% |
| Geode Capital Management, LLC | 2,188,890 | 2.70% | $610.44M | +2,948 | 0.03% |
| Select Equity Group, L.P. | 1,981,948 | 2.44% | $554.95M | −192,837 | 2.74% |
| FMR LLC | 1,904,870 | 2.35% | $533.36M | +616,459 | 0.02% |
| Morgan Stanley | 1,609,447 | 1.98% | $450.65M | +111,420 | 0.02% |
| Dimensional Fund Advisors LP | 1,367,166 | 1.69% | $382.80M | +34,391 | 0.07% |
| JPMorgan Chase & Co | 1,268,384 | 1.56% | $354.62M | −264,339 | 0.02% |
| Invesco Ltd. | 1,237,676 | 1.53% | $346.55M | −78,521 | 0.03% |
| Nordea Investment Management Ab | 915,939 | 1.13% | $254.72M | −129,203 | 0.21% |
| UBS Asset Management Americas Inc | 887,431 | 1.09% | $248.48M | −12,771 | 0.05% |
| Northern Trust Corp | 883,076 | 1.09% | $247.26M | −114,334 | 0.03% |
| Wellington Management Group Llp | 855,596 | 1.05% | $239.57M | −103,543 | 0.04% |
| American Century Companies Inc | 845,023 | 1.04% | $236.61M | +34,218 | 0.10% |
| Bank Of America Corp /De/ | 812,270 | 1.00% | $227.44M | +87,459 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,043 | 79M | 98.0% | 107 / 358 | 390 / 72 | 6M | 4M |
| Q1 2026 | 1,022 | 78M | 96.4% | 107 / 332 | 378 / 90 | 14M | 7M |
| Q4 2025 | 1,016 | 80M | 99.1% | 140 / 307 | 387 / 105 | 10M | 8M |
| Q3 2025 | 996 | 79M | 96.9% | 107 / 314 | 378 / 59 | 5M | 7M |
| Q2 2025 | 962 | 81M | 100.0% | 104 / 339 | 360 / 91 | 9M | 5M |
| Q1 2025 | 963 | 78M | 96.4% | 115 / 330 | 351 / 49 | 6M | 5M |
| Q4 2024 | 912 | 78M | 96.4% | 116 / 337 | 333 / 92 | 7M | 7M |
| Q3 2024 | 906 | 78M | 96.7% | 159 / 299 | 302 / 58 | 14M | 6M |
| Q2 2024 | 811 | 79M | 97.7% | 809 / 0 | 0 / 0 | 79M | 0M |
| Q1 2024 | 3 | 0M | 0.0% | 2 / 0 | 0 / 3 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0.0% | 1 / 1 | 1 / 0 | 0M | 0M |
| Q3 2023 | 3 | 0M | 0.0% | 0 / 3 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,603,810 | 3.21% | $729.07M | 0.03% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 2,124,615 | 2.62% | $594.89M | 0.04% | Jun 30, 2026 |
| Vanguard Mid-Cap Index Fund | 1,776,838 | 2.19% | $497.51M | 0.22% | Jun 30, 2026 |
| Allspring Special Mid Cap Value Fund | 1,536,100 | 1.89% | $430.11M | 3.19% | Jun 30, 2026 |
| Victory Sycamore Established Value Fund | 1,445,000 | 1.78% | $404.60M | 2.62% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 1,128,386 | 1.39% | $315.95M | 0.04% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 1,060,876 | 1.31% | $275.89M | 0.03% | May 31, 2026 |
| Victory Pioneer Fund | 1,051,948 | 1.30% | $294.55M | 2.63% | Jun 30, 2026 |
| Vanguard Value Index Fund | 779,826 | 0.96% | $218.35M | 0.09% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 694,336 | 0.86% | $214.69M | 0.22% | Jul 31, 2026 |
| Fidelity Low-Priced Stock Fund | 684,395 | 0.84% | $211.61M | 0.85% | Jul 31, 2026 |
| Vanguard Windsor Ii Fund | 622,300 | 0.77% | $192.42M | 0.29% | Jul 31, 2026 |
| The Hartford Dividend And Growth Fund | 610,718 | 0.75% | $188.83M | 1.00% | Jul 31, 2026 |
| Disciplined Value Mid Cap Fund | 598,151 | 0.74% | $167.48M | 0.72% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 579,364 | 0.71% | $162.22M | 0.40% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adam H. Schechter | President & CEO, Director | 102,565 | 0.13% | Aug 12, 2026 |
| Bryan T. Vaughn | EVP and President, Diagnostics | 6,746 | 0.01% | Sep 3, 2026 |
| Jonathan C. Meltzer | EVP, COO | 3,620 | 0.00% | Sep 3, 2026 |
| Brian J. Caveney | EVP, Pres of BLS, CMO & CSO | 36,492 | 0.04% | Sep 3, 2026 |
| Akinbolade Oyegunwa | EVP, CIO & CTO | 5,064 | 0.01% | Sep 3, 2026 |
| Amy B. Summy | EVP, Chief Marketing Officer | 6,956 | 0.01% | Aug 6, 2026 |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 1,770 | 0.00% | Aug 5, 2026 |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 3,904 | 0.00% | Jul 6, 2026 |
| Anita Z. Graham | EVP, CHRO | 5,185 | 0.01% | Mar 30, 2026 |
| Megan D. Bailey | EVP, Pres, Central Labs & Intl | 5,332 | 0.01% | Mar 30, 2026 |
| der Vaart Sandra D. van | EVP, Corporate Affairs | 6,239 | 0.01% | Mar 30, 2026 |
| Mark S. Schroeder | EVP, Pres Diagnostics & COO | 15,777 | 0.02% | Mar 30, 2026 |
| Julia Aijun Wang | Chief Financial Officer, EVP | 1,817 | 0.00% | Feb 13, 2026 |
| Glenn A. Eisenberg | Executive Vice President | 41,550 | 0.05% | Mar 31, 2025 |
| Lance Berberian | EVP, Special Advisor, Strategy | 20,005 | 0.02% | Mar 31, 2025 |
| Kerrii B. Anderson | Director | 6,851 | 0.01% | Aug 18, 2026 |
| Kirsten Marie Kliphouse | Director | 3,160 | 0.00% | Feb 13, 2026 |
| Peter M. Neupert | Director | 13,784 | 0.02% | Feb 13, 2026 |
| Jeffrey A. Davis | Director | 5,460 | 0.01% | Feb 13, 2026 |
| Garheng Kong | Director | 13,739 | 0.02% | Feb 13, 2026 |
| Paul Rothman | Director | 2,571 | 0.00% | Feb 13, 2026 |
| Richelle P. Parham | Director | 3,366 | 0.00% | Feb 13, 2026 |
| Kathryn E. Wengel | Director | 4,133 | 0.01% | Feb 13, 2026 |
| John H. Sampson | Director | – | – | Feb 12, 2026 |
| Carulla Victor Bulto | Director | – | – | Feb 12, 2026 |
| Dwight Gary Gilliland | Director | 6,656 | 0.01% | Aug 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kerrii B. Anderson Director | Aug 17, 2026 | Sale(10b5-1 plan) | −3,000 | $318.02 | $954.06K | 6,563 |
| Adam H. Schechter President & CEO, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −4,669 | $320.37 | $1.50M | 102,565 |
| Amy B. Summy EVP, Chief Marketing Officer | Aug 4, 2026 | Sale | −924 | $306.74 | $283.43K | 6,956 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Sale | −82 | $309.22 | $25.36K | 1,770 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Option exercise | +1,338 | $209.25 | $279.98K | 3,108 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Aug 3, 2026 | Sale | −1,338 | $309.23 | $413.75K | 1,770 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −92 | $286.19 | $26.33K | 3,904 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 2, 2026 | Sale(10b5-1 plan) | −234 | $286.19 | $66.97K | 6,746 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 1, 2026 | Tax withholding | −73 | $283.88 | $20.72K | 3,996 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jul 1, 2026 | Option exercise | +256 | – | – | 4,069 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 1, 2026 | Option exercise | +327 | – | – | 7,073 |
| Bryan T. Vaughn EVP and President, Diagnostics | Jul 1, 2026 | Tax withholding | −93 | $283.88 | $26.40K | 6,980 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Jun 8, 2026 | Sale(10b5-1 plan) | −762 | $263.89 | $201.08K | 3,813 |
| Adam H. Schechter President & CEO, Director | May 11, 2026 | Sale(10b5-1 plan) | −5,903 | $254.50 | $1.50M | 107,234 |
| Jonathan C. Meltzer EVP, Operations | Mar 27, 2026 | Sale(10b5-1 plan) | −839 | $267.05 | $224.05K | 3,620 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 27, 2026 | Sale(10b5-1 plan) | −1,633 | $267.05 | $436.09K | 1,852 |
| Adam H. Schechter President & CEO, Director | Mar 26, 2026 | Award | +58,470 | – | – | 139,243 |
| Adam H. Schechter President & CEO, Director | Mar 26, 2026 | Tax withholding | −26,106 | $268.38 | $7.01M | 113,137 |
| Jonathan C. Meltzer EVP, Operations | Mar 26, 2026 | Tax withholding | −711 | $268.38 | $190.82K | 4,459 |
| Jonathan C. Meltzer EVP, Operations | Mar 26, 2026 | Award | +2,388 | – | – | 5,170 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 26, 2026 | Award | +2,388 | – | – | 4,240 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Mar 26, 2026 | Tax withholding | −755 | $268.38 | $202.63K | 3,485 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Mar 26, 2026 | Tax withholding | −382 | $268.38 | $102.52K | 5,064 |
| Akinbolade Oyegunwa EVP, CIO & CTO | Mar 26, 2026 | Award | +1,340 | – | – | 5,446 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Mar 26, 2026 | Tax withholding | −451 | $268.38 | $121.04K | 4,575 |
| Kathryn W. Kyle EVP, Chief Legal Officer | Mar 26, 2026 | Award | +1,584 | – | – | 5,026 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Tax withholding | −863 | $268.38 | $231.61K | 36,492 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Award | +1,986 | – | – | 37,355 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Tax withholding | −4,042 | $268.38 | $1.08M | 35,369 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Mar 26, 2026 | Award | +9,304 | – | – | 39,411 |
| Anita Z. Graham EVP, CHRO | Mar 26, 2026 | Tax withholding | −2,879 | $268.38 | $772.67K | 5,185 |
| Anita Z. Graham EVP, CHRO | Mar 26, 2026 | Award | +6,604 | – | – | 8,064 |
| Megan D. Bailey EVP, Pres, Central Labs & Intl | Mar 26, 2026 | Award | +1,184 | – | – | 5,332 |
| Megan D. Bailey EVP, Pres, Central Labs & Intl | Mar 26, 2026 | Tax withholding | −481 | $268.38 | $129.09K | 4,851 |
| Amy B. Summy EVP, Chief Marketing Officer | Mar 26, 2026 | Tax withholding | −1,836 | $268.38 | $492.75K | 7,880 |
| Amy B. Summy EVP, Chief Marketing Officer | Mar 26, 2026 | Award | +3,994 | – | – | 9,716 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Award | +9,304 | – | – | 15,777 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Tax withholding | −4,600 | $268.38 | $1.23M | 11,177 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Award | +2,968 | – | – | 14,145 |
| Mark S. Schroeder EVP, Pres Diagnostics & COO | Mar 26, 2026 | Tax withholding | −1,468 | $268.38 | $393.98K | 12,677 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Mar 26, 2026 | Tax withholding | −2,722 | $268.38 | $730.53K | 6,239 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Mar 26, 2026 | Award | +6,382 | – | – | 8,961 |
| Bryan T. Vaughn EVP, Diagnostics | Mar 26, 2026 | Tax withholding | −451 | $268.38 | $121.04K | 6,746 |
| Bryan T. Vaughn EVP, Diagnostics | Mar 26, 2026 | Award | +1,584 | – | – | 7,197 |
| Adam H. Schechter President & CEO, Director | Mar 3, 2026 | Sale | −8,705 | $279.96 | $2.44M | 80,773 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Feb 27, 2026 | Sale | −547.54 | $284.91 | $156.00K | 2,579 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 24, 2026 | Sale | −1,500 | $286.31 | $429.47K | 30,107 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 19, 2026 | Sale(10b5-1 plan) | −666 | $277.94 | $185.11K | 1,852 |
| Jonathan C. Meltzer EVP, Operations | Feb 12, 2026 | Sale(10b5-1 plan) | −87 | $290.42 | $25.27K | 2,782 |
| Garheng Kong Director | Feb 11, 2026 | Option exercise | +897 | – | – | 13,739 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 11, 2026 | Tax withholding | −211 | $289.89 | $61.17K | 31,607 |
| Brian J. Caveney EVP, Pres of ED, CMO & CSO | Feb 11, 2026 | Option exercise | +740 | – | – | 31,818 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Feb 11, 2026 | Option exercise | +376 | – | – | 3,225 |
| der Vaart Sandra D. van EVP, Corporate Affairs | Feb 11, 2026 | Tax withholding | −99 | $289.89 | $28.70K | 3,126 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 11, 2026 | Option exercise | +160 | – | – | 2,564 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 11, 2026 | Tax withholding | −46 | $289.89 | $13.33K | 2,518 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 11, 2026 | Option exercise | +536 | – | – | 2,564 |
| Peter J. Wilkinson SVP, Chief Accounting Officer | Feb 11, 2026 | Tax withholding | −160 | $289.89 | $46.38K | 2,404 |
| Paul Rothman Director | Feb 11, 2026 | Option exercise | +897 | – | – | 2,571 |
| Jonathan C. Meltzer EVP, Operations | Feb 11, 2026 | Option exercise | +243 | – | – | 2,939 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| B. Anderson Kerrii Director | Aug 17, 2026 | 3,000 | $954.39K | Aug 17, 2026 | Restricted Stock Awards |
| Adam H. Schechter Officer, Director | Aug 11, 2026 | 4,669 | $1.50M | Aug 11, 2026 | Restricted Stock Vesting |
| Amy B. Summy Officer | Aug 4, 2026 | 924 | $283.43K | Aug 4, 2026 | Restricted Stock Vesting |
| Kathryn W. Kyle Officer | Jul 2, 2026 | 92 | $26.33K | Jul 2, 2026 | Restricted Stock Vesting |
| Bryan T. Vaughn Officer | Jul 2, 2026 | 234 | $66.97K | Jul 2, 2026 | Restricted Stock Vesting |
| der Vaart Sandra D. van Former Officer | Jul 1, 2026 | 7,138 | $2.00M | Jul 1, 2026 | Stock Option Exercise |
| Kathryn W. Kyle Officer | Jun 8, 2026 | 762 | $201.08K | Jun 8, 2026 | Restricted Stock Vesting |
| Adam H. Schechter Officer, Director | May 11, 2026 | 5,903 | $1.50M | May 11, 2026 | Restricted Stock Vesting |
| der Vaart Sandra D. van Former Officer | May 6, 2026 | 6,238 | $1.60M | May 6, 2026 | Restricted Stock Vesting |
| Jonathan C. Meltzer Officer | Mar 27, 2026 | 839 | $224.05K | Mar 27, 2026 | Restricted Stock Vesting |
| Adam H. Schechter Officer, Director | Mar 3, 2026 | 8,705 | $2.44M | Mar 3, 2026 | Restricted Stock Vesting |
| der Vaart Sandra D. van Officer | Feb 27, 2026 | 548 | $156.00K | Feb 27, 2026 | Restricted Stock Vesting |
| Brian J. Caveney Officer | Feb 24, 2026 | 1,500 | $429.46K | Feb 24, 2026 | Restricted Stock Vesting |
| Jonathan C. Meltzer Officer | Feb 12, 2026 | 87 | $25.27K | Feb 12, 2026 | Restricted Stock Vesting |
| Adam H. Schechter Officer, Director | Feb 11, 2026 | 5,273 | $1.50M | Feb 11, 2026 | Restricted Stock Vesting |